Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis.
Candesant Biomedical has raised $35.0M in total funding. The most recent round was Series B. The last funding was announced in June 2023.
Candesant Biomedical's investors include Polaris Partners, Correlation Ventures, Astia, KCK Medtech.
Candesant Biomedical is headquartered in San Francisco, United States.
Candesant Biomedical develops treatment for excessive sweating and hyperhidrosis.
Candesant Biomedical is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Candesant Biomedical — Funding & Investors." VCBacked, June 6, 2023, https://www.vcbacked.co/company/candesant-biomedical. Accessed October 4, 2026.
VCBacked. (2023). Candesant Biomedical — Funding & Investors. Retrieved October 4, 2026, from https://www.vcbacked.co/company/candesant-biomedical
{{cite web |title=Candesant Biomedical — Funding & Investors |url=https://www.vcbacked.co/company/candesant-biomedical |website=VCBacked |access-date=October 4, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated